It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.09.23289707;](https://doi.org/10.1101/2023.05.09.23289707) this version posted May 11, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted med

Capturing heterogeneity in Opisthorchis viverrini epidemiology and control

Lars Kamber *^{1,2}, Christine Bürli^{1,2}, Helmut Harbrecht³, Peter Odermatt^{1,2}, Somphou Sayasone^{1,2,4}, and Nakul Chitnis^{1,2}

¹Swiss Tropical and Public Health Institute, Allschwil, Switzerland ²University of Basel, Basel, Switzerland

³Department of Mathematics and Computer Science, University of Basel, Basel, Switzerland

⁴Lao Tropical and Public Health Institute, Vientiane, Lao PDR

May 5, 2023

Abstract

Opisthorchis viverrini is a parasitic liver fluke affecting over 10 million people despite sustained control efforts. High intensity infections are a risk factor for the often fatal bile duct cancer, cholangiocarcinoma. Similar to other helminthiases, the distribution of worm burden in humans is highly uneven within populations. We developed multiple models which allow us to capture heterogeneity in transmission and interventions dynamics and the resulting impact on worm distribution: An agent-based model with the common assumption of gamma-distributed transmission parameters; an agent-based model with an alternative nonparametric distribution of transmission parameters; and a simpler ordinary differential equation model. We calibrated all models to prevalence and intensity of infection data in humans, and prevalence data for reservoir hosts and intermediate hosts from southern Lao People's Democratic Republic. We simulated the impact of multiple interventions on prevalence, intensity of infection and the distribution of worm burden in humans. Our results showed significant overlap in predictions of prevalence and intensity of infection over time between the agent-based models and the ordinary differential equation model, corroborating both the simple and more complex models; however, the nonparametric model was better able to capture the distribution of the highest intensity burden in individuals. Under assumptions of homogeneous adherence to mass drug administration campaigns, no model was able to capture the changing heterogeneity of worm burden over time seen in the epidemiological data. Allowing for heterogeneous adherence in these campaigns, which was only possible in the agent-based models, allowed us to explain the changes seen in the worm distribution and burden seen in the data. This result highlights the added benefit of agent-based models in capturing the changing heterogeneity in worm burden in areas with repeated mass treatments. Appropriately capturing this heterogeneity is essential in understanding the relationship between worm burden, control interventions and subsequent disease burden.

^{*}Corresponding author. Email: lars.kamber@swisstph.ch

Author summary

Opisthorchis viverrini is a parasitic liver fluke affecting over 10 million people despite sustained control efforts. The distribution of worm burden in humans is highly uneven within populations with high intensity infections being a major risk factor for bile duct cancer. We developed and present multiple models, some of which allow us to capture this uneven distribution in susceptibility to infection as well as in adherence to treatment: Two agent-based models of high complexity and a simpler population-based model. We calibrated all models to replicate worm burden data collected in southern Lao People's Democratic Republic. We simulated the impact of multiple interventions and showed significant overlap of all models in many aspects, corroborating both the simple and more complex models. However, we show that the agent-based models have the added benefit of being able to better capture the unevenness of worm burden before and especially after interventions.

1 Introduction ¹

Opisthorchis viverrini is a parasitic liver fluke endemic to the Greater Mekong ² Subregion (GMS) in Southeast Asia [\[1\]](#page-17-0). While substantial reductions in O . *viverrini* prevalence were achieved over recent decades, a total of 12.4 million individuals in the ⁴ GMS were estimated to still be infected in 2018 $[2-4]$ $[2-4]$. Infections with O. viverrini can be asymptomatic [\[5\]](#page-17-3) but frequently cause liver morbidity and, especially after sustained heavy infection, cholangiocarcinoma, a malignancy with poor prognosis [\[6](#page-17-4)[–9\]](#page-17-5).

Humans and other mammals, such as dogs and cats, serve as definitive hosts of O. ⁸ *viverrini* [\[10\]](#page-17-6). The mature parasite resides in the bile duct producing eggs which reach the environment with the hosts' stool. *Miracidia* hatch from eggs and are ingested by $\frac{10}{20}$ freshwater snails of the genus *Bithynia*, inside which they develop into *cercariae*. The 11 cercariae shed from the snails, penetrate the skin of fish from the carp family and ¹² develop into *metacercariae* inside the fish. When definitive hosts consume infected fish 13 in raw or undercooked form, the *metacercariae* migrate to the hosts' bile duct and develop into adult worms that can live for many years . 15

The intensity of liver fluke infection is highly heterogeneous in populations where $\frac{16}{16}$ O. viverrini is endemic, with relatively few individuals exhibiting very heavy worm 17 burden $[11]$. This pattern of aggregation is typical for macroparasitic infections and $\frac{1}{18}$ has been explained by differences in exposure, susceptibility and immune response of $\frac{1}{2}$ $\text{individuals } [12, 13].$ $\text{individuals } [12, 13].$ $\text{individuals } [12, 13].$ $\text{individuals } [12, 13].$ $\text{individuals } [12, 13].$

Praziquantel is the drug of choice for the treatment of O . *viverrini* infection. Non-pharmaceutical interventions include education campaigns on safe fish 22 consumption and use of sanitation, improvement of sanitation, snail control and safe 23 fish farming. Mass drug administration (MDA) campaigns with Praziquantel are ²⁴ regularly conducted in endemic areas, but with limited success $[14]$. While the drug $\frac{25}{25}$ itself shows high efficacy when dosed correctly, infection prevails because of limited $_{26}$ coverage, limited adherence and continued consumption of raw and undercooked fish. 27

In previous work, we developed various population-based models (PBMs) for O . \qquad 28 viverrini transmission and control. These are ordinary and partial differential 29 equation models that track the mean worm burden in humans and reservoir hosts, and $\frac{30}{20}$ the prevalence of infection in intermediate hosts. The main conclusions from PBM $_{31}$ studies are that interruption of transmission can be achieved by only targeting humans $\frac{32}{2}$ with interventions $[15]$, but MDA campaigns covering all age groups are necessary to $\frac{33}{2}$ interrupt transmission and treating school-aged children exclusively is not sufficient to $\frac{34}{4}$ achieve this goal [\[16\]](#page-18-5). Other modelling work on O. viverrini has focused on the effect $\frac{35}{25}$ of ecological and climate factors on transmission $[17, 18]$ $[17, 18]$ $[17, 18]$. Furthermore, several $\frac{36}{15}$

> compartmental models for the transmission and control of *Clonorchis sinensis*, a $\frac{37}{2}$ parasite with the same life cycle as $O.$ viverrini, have been published $[19-23]$ $[19-23]$.

> While PBMs can provide distributions of worm burden as an output based on $\frac{39}{20}$ mean worm burden $[12]$, they usually assume homogeneity of individuals when it comes to susceptibility to infection, behavior, adherence to interventions and coverage ⁴¹ of interventions. PBMs can accommodate for heterogeneity to some degree by adding ⁴² compartments for each combination of considered characteristics. For example, ⁴³ separate compartments were added for individuals with different propensity to ⁴⁴ consume undercooked fish in a PBM for C. sinensis $[21]$. However, when modelling $\qquad 45$ multiple sources of heterogeneity simultaneously, the number of required 46 compartments grows exponentially. Agent-based models (ABMs) track each individual ⁴⁷ separately, allowing heterogenous characteristics, and tracking parasite and disease $\frac{48}{48}$ burden at the individual level. Because heterogeneities among humans play an ⁴⁹ important role in the transmission, pathology and treatment of O . *viverrini*, we have \sim developed an ABM for *O. viverrini* transmission and control. To our knowledge, this $\frac{51}{100}$ is the first model of this kind for O. viverrini or C. sinensis. We present two versions 52 of the ABM: One with the assumption of gamma-distributed transmission parameters $\frac{53}{12}$ over the population, which is the most common assumption in ABMs of $_{54}$ schistosomiasis $[24]$, and one with a nonparametric distribution of transmission \sim parameters derived from the distribution of worm burden in two villages in Lao PDR. $\frac{56}{100}$ We fit both models to this data and compare the equilibrium state and intervention $\frac{57}{2}$ impact predictions to those of a previously published PBM of $O.$ viverrini $\frac{58}{100}$ transmission and control $[25]$. We show that taking heterogeneities into account is $\frac{59}{25}$ essential to adequately model the impact of interventions on worm distribution.

2 Methods $\frac{1}{61}$

2.1 Data $\frac{1}{2}$

We use previously published data collected in cross-sectional surveys on two adjacent 63 Mekong river islands in Southern Laos in 2012 and 2018 [\[11\]](#page-18-0). Between the surveys, $\frac{64}{64}$ MDA was conducted every year except in 2013 and education campaigns were carried $\frac{65}{65}$ out. The 2012 data includes the intensity of infection for *O. viverrini* measured in 66 eggs per gram of stool (EPG) in stool samples of humans, cats and dogs. It also $\frac{67}{67}$ includes prevalence of infection in the intermediate snail and fish hosts. For the year $\overline{68}$ 2018, only EPG data in humans is available. The number of samples of each kind are listed in Table [1](#page-2-0) and the distribution of EPG among humans is shown in Fig [1.](#page-3-0) We σ transform EPG to worm counts and vice versa in individuals and animals with a ⁷¹ density-dependent function derived from a purging study as described in the $\frac{72}{2}$ $supplementary Section S1.6.2.$

Table 1. Number of tested and positive samples from definitive and intermediate hosts in 2012 and 2018.

Fig 1. Distribution of EPG among humans in data collected in 2012 and 2018. The hatched wide bars on the left show the proportion of individuals with an egg count of zero. The remaining bars show the proportion of individuals with nonzero egg counts, where the bin width equals 1000 EPG. The red lines mark the thresholds of World Health Organization worm burden classification with 1-999 EPG being classified as light infection, 1000-9999 as moderate infection and 10000 and above as heavy infection [\[26\]](#page-19-1). The EPG data from both years show a high degree of aggregation, $k = 0.10$ in 2012 and $k = 0.03$ in 2018, implying more aggregation in 2018. These values of k are obtained by applying Equation (3) to the EPG data.

2.2 Agent-based Model 74

This section provides a high-level overview of the ABM. A detailed description written τ according to the ODD (Overview, Design concepts, Details) protocol for describing $\frac{56}{100}$ individual- and agent-based models $[27, 28]$ $[27, 28]$ $[27, 28]$ is provided in the supplementary $\overline{77}$ Section S1. A schematic of the ABM is provided in Fig [2.](#page-4-0) State variables of N_{eq} humans are tracked individually while animals are modelled at the aggregate level (Table [2\)](#page-4-1). The transmission dynamics are governed by the parameters listed in $\frac{80}{100}$ Table [3.](#page-5-0) We introduce heterogeneity by letting the worm acquiring rate $\beta_{hf,i}$ vary $\beta_{hf,i}$ between individuals, *i*. We consider two distributions for randomly drawing $\beta_{hf,i}$ and ⁸² refer to the models using these distributions with separate names: The ABM^{Γ} assumes $\frac{1}{100}$ a gamma distribution, which can be considered the standard assumption for ⁸⁴ macroparasite models [\[24\]](#page-18-11); the AMB^{ε} assumes a nonparametric distribution derived $\frac{1}{100}$ from the 2012 field data. The gamma distribution in the ABM^{Γ} is parameterized by the mean and variance parameters β_{μ}^{Γ} and β_{σ}^{Γ} whose values are determined by model \Box fitting. In the AMB^{ε}, a worm count \tilde{w}_i is drawn for each individual from the distribution of worm counts in the 2012 data. The individuals' $\beta_{hf,i}$ is derived from \qquad the drawn \tilde{w}_i using the relation $\frac{1}{2}$

$$
\log_{10}(\beta_{hf,i}) = \beta_a^{\varepsilon} + \beta_b^{\varepsilon} \log_{10}(\tilde{w}_i),\tag{1}
$$

for nonzero values of \tilde{w}_i , where β_a^{ε} and β_b^{ε} are parameters that are determined by model fitting. If \tilde{w}_i equals zero, $\beta_{hf,i}$ is set to zero as well.

For all humans and animals the uptake of new parasites is Poisson distributed with $\frac{93}{2}$ a rate determined by the current state of the system, the transmission parameters, the $\frac{94}{94}$ time step size and the population sizes. We choose a time step size of one month and a $\frac{1}{95}$ population size of 100,000 for fitting and the analyses in this paper.

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.09.23289707;](https://doi.org/10.1101/2023.05.09.23289707) this version posted May 11, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted med

Fig 2. Schematic of the the agent-based model for *O. viverrini* transmission and control. The state variables are described in Table [2](#page-4-1) and the transmission parameters are described in Table [3.](#page-5-0) Worm counts are mapped to egg output with a nonlinear monotonically increasing piecewise function ρ derived from purging studies (Section S1.6.2). While ρ is applied to the mean worm burden in cats and dogs and then multiplied with the number of cats and dogs, respectively, it is applied to each individual worm count in humans and subsequentially summed up over humans.

Table 2. State variables in the ABM. All variables with superscript (t) can change over time. The upper part of the table contains the variables which are tracked for each individual human as indicated by subscript i . The lower part of the table contains the state variables of nonhuman hosts. The maximum number of worms an individual can carry is set to a biologically implausible value to facilitate the parameter fitting process and is never reached under fitted parameter values.

Parameter	Description	Unit
β_{sh}	Transmission rate to snails from eggs in hu-	$1/(\text{Day} \times \text{Animals})$
	man stool	
β_{sd}	Transmission rate to snails from eggs in dog	$1/(\text{Day} \times \text{Animals})$
	stool	
β_{sc}	Transmission rate to sanils from eggs in cat	$1/(Day \times Animals)$
	stool	
β_{fs}	Transmission rate to fish from snails	$1/(\text{Day} \times \text{Animals})$
$\beta_{hf,i}$	Transmission rate to individual <i>i</i> from fish	$1/(\text{Day} \times \text{Animals})$
β_{df}	Transmission rate to dogs from fish	$1/(\text{Day} \times \text{Animals})$
β_{cf}	Transmission rate to cats from fish	$1/(\text{Day} \times \text{Animals})$

Table 3. Transmission parameters of the ABM. Further parameters of the ABM are described in the supplementary Section S1.6.

2.3 Population-based model and the state of the state

The PBM we use for comparison with the ABM is an ordinary differential equation $\frac{98}{98}$ model that has been described and analysed in previous work $[15, 25]$ $[15, 25]$ $[15, 25]$. A schematic of $\frac{99}{2}$ the model is given in Fig 3 . The equations and a complete table of parameters are 100 given in the supplementary Section S2.

Fig 3. Schematic of the population-based model for *O. viverrini* transmission and control. The state variables are described in Table [4,](#page-6-1) the transmission parameters roughly correspond to the transmission parameters of the ABM listed in Table [3.](#page-5-0) As opposed to the ABM, where β_{h} varies over individuals, there is only a single β_{hf} in the PBM. Also, the PBM does not translate worm burden in definitive hosts to egg output which results the in the transmission parameters β_{sh} , β_{sd} and β_{sc} acting on mean worm burden instead of egg count. Further details of the PBM are provided in supplementary Section S2.

Instead of tracking worms in humans individually, the PBM tracks the mean $_{102}$ number of worms across humans. This means that the PBM, as opposed to the ABM, $_{103}$ does not provide a distribution of worm burden and therefore prevalence as a direct $_{104}$ output. To obtain a distribution, we use a negative binomial parameterized by an ¹⁰⁵

	Variable Description
w_h	Mean worm burden per human host
w_d	Mean worm burden per dog host
w_c	Mean worm burden per cat host
i_s	Proportion of infectious snails
$i_{\mathbf{f}}$	Proportion of infectious fish

Table 4. State variables of the population-based model.

 α aggregation parameter k having the probability mass function,

$$
p(w_i) = \frac{(k+w_i-1)!}{i!(k-1)!} (1+w_h/k)^{-k-i} (w_h/k)^i,
$$
\n(2)

which provides the distribution of worm counts, w_i , for a given mean worm burden, 107 w_h [\[12\]](#page-18-1). The prevalence, P, which corresponds to the proportion of non-zero worm 108 counts, is given by $\frac{109}{200}$

$$
P = 1 - (1 + w_h/k)^{-k}.
$$
 (3)

We substitute the mean worm burden and prevalence from the field data collected 110 in 2012 for w_h and P in Equation [\(3\)](#page-6-0) and solve numerically for k to estimate the level μ of aggregation in the field data. We then assume k to be constant over time $[12]$ and 112 substitute the calculated value of k into Equation (2) to obtain a distribution of $\frac{1}{133}$ individual worm burden, w_i , for any mean worm burden, w_h , calculated during a PBM $_{114}$ $\rm model~run.$ 115

2.4 Transmission parameter fitting $\frac{116}{116}$

We fit the transmission parameters included in Table [3](#page-5-0) to the 2012 data. The data $\frac{117}{117}$ from 2018 is not used to fit transmission parameters. For both ABMs, we fit the 118 parameters which govern the distribution of β_{h} , as described in Section [2.2.](#page-3-1) The 119 parameters β_{sh} , β_{sc} and β_{sd} are not identifiable for all models given the data and we 120 fix these three parameters to be equal to a parameter β_{sx} which is fitted instead.

The transmission parameters are calibrated such that the models reach an 122 equilibrium that matches various target summary statistics calculated from the 2012 123 data listed in Table [5.](#page-7-0) To create summary statistics that capture the worm ¹²⁴ distribution in a clinically significant way, we bin the worm burden of positive humans 125 into 3 categories according to World Health Organization criteria $[26]$: Individuals 126 having between 1 EPG and 999 EPG are classified as having low worm burden, 127 between 1,000 EPG and 9,999 EPG as medium worm burden and above 10,000 EPG ¹²⁸ as high worm burden. The summary statistics used for fitting are the proportions of $_{129}$ individuals that have low, medium or high worm burden as well as the mean of EPG 130 within each of those groups. We use these distributional summary statistics only for $\frac{131}{131}$ the fitting of the ABM^{ε}, as the ABM^{Γ} and the PBM cannot reach the target 132 prevalence when simultaneously being fitted to the distributional target values. In 133 contrast, the distribution of β_{h} , in the ABM^{ϵ} has a proportion of individuals with a 134 value of zero that results in the target prevalence by design.

We fit the ABMs using Trust Region Bayesian Optimization (TuRBO) with local 136 Gaussian processes implemented with the Python package BoTorch $[29, 30]$ $[29, 30]$ $[29, 30]$. The PBM $_{137}$ parameters required to reach a target equilibrium were calculated analytically. ¹³⁸

Table 5. Target summary statistic values used to fit transmission parameters. A bullet signifies that the summary statistic was used to fit the respective model.

2.5 Mass drug administration modelling 139

For the comparison of intervention impact predictions, we start all models at 140 equilibrium, run them for one year without interventions and subsequently deploy $_{141}$ yearly MDA for five years with coverages constant over time ranging from 0% to 90% . In the ABMs, this corresponds to reducing the worm count to 0 for a random selection $_{143}$ of individuals corresponding to the coverage. For the PBM model, we reduce the mean ¹⁴⁴ worm count by the MDA coverage. We run each ABM simulation with 10 random 145 seeds. To compare the predictions over different coverages we assess the state variables $_{146}$ one year after the last round of MDA. This scheme of five years of MDA and ¹⁴⁷ subsequent assessment approximates the MDA and survey scheme of the population $_{148}$ from which the data in 2012 and 2018 was obtained (Section [2.1\)](#page-2-1). ¹⁴⁹

2.6 Heterogeneity in access to MDA and education campaign $_{150}$

In order to match the model predictions for prevalence and mean worm burden to the 151 2018 data in a second step, we employ heterogeneity in MDA adherence and include 152 an education campaign. For modelling heterogeneity in MDA adherence, treatment is $_{153}$ still distributed randomly but individuals have different probabilities of being reached ¹⁵⁴ by MDA campaigns which stay fixed over time. We assume these probabilities to 155 follow a beta distribution with mean 0.8 and examine a range of variances between 0_{156} and 0.3, where a larger variance implies increased heterogeneity. The mean of 0.8 157 translates to a coverage of 80% , which corresponds to the estimated effective coverage $\frac{158}{158}$ in the study area between 2012 and 2018 as estimated by expert opinion. We assign $\frac{159}{200}$ the drawn probabilities of MDA participation to individuals in descending order of $_{160}$ their $\beta_{hf,i}$. This means that those individuals with the highest rate of acquiring $\beta_{hf,i}$. worms $\beta_{h}f_{i}$ are least likely to be reached by the MDA campaign. As the individuals' 162 probabilities of being reached during the MDA campaigns stays fixed over time, this ¹⁶³ also implies serial correlation of MDA adherence.

For the yearly education campaign, we assume that all individuals are reached and $_{165}$ that, for each campaign, the effect is the multiplication of $\texttt{beta_multiplier}_i^{(t)}$ with a 166 factor equal to one minus the education campaign's efficacy, which we examine within $_{167}$ a range of 0 to 0.5. $\frac{168}{168}$

We run simulations for one year in equilibrium followed by five years of yearly 169 MDA and education campaigns and assess the state variables one year after the final 170

> intervention. The simulations are run over combinations within the explored range of $_{171}$ MDA variance and education campaign efficacy. Using Gaussian process regression, 172 we predict the combinations of education campaign efficacy and MDA variance which $_{173}$ reproduce the mean worm burden and prevalence from the 2018 data at the end of the ¹⁷⁴ $\rm model~run.$ 175

3 Results 176

We obtain good fits in equilibrium for all the the target summary statistics used for $\frac{177}{177}$ fitting with the parameter values listed in Table [6.](#page-8-0) A kernel density estimate of the $_{178}$ worm distribution among the individuals in the 2012 data and in the models at 179 equilibrium is provided in Fig [4.](#page-9-0) It shows a very high agreement between the ABM^{ε} and the data, while the equilibrium state of the PBM and the ABM^{Γ} are very similar 181 but show some discrepancy to the data. This high agreement in equilibrium worm 182 distribution between ABM^{Γ} and the PBM can be expected, since we assume that the 183 worm uptake of individuals in the ABMs follows a Poisson distribution at each time $step.$ 185

The goodness of fit can also be evaluated by comparing the 2012 data with the 186 model states in equilibrium at the beginning of the time series in Fig 5 . While all $_{187}$ models can fit the prevalence and mean worm burden targets (Fig [5a\)](#page-11-0), only the ABM^{ϵ} can fit all distributional targets as well (Fig [5b\)](#page-11-0). The PBM and the ABM^{Γ} show the 189 same pattern in derivation from the data at equilibrium: They underestimate the 190 prevalence and mean EPG for the group with low worm burden while the reverse is ¹⁹¹ true for the moderate worm burden: both the PBM and the ABM^{Γ} overestimate the 192 prevalence of individuals in this group and the mean EPG within this group. Finally, ¹⁹³ for the high worm burden, there is a slight underestimation of the mean worm burden 194 within this group by the ABM^{Γ} and the PBM, while all models fit the prevalence of $_{195}$ high worm burden well. 196

Table 6. Fitted parameter values for all models. The first five parameters in the table are parameters determining the transmission from snails to humans and are specific to the respective models. The remaining parameters are part of all three models. The fitted values for β_{df} , β_{cf} and β_{fs} are very close to each other for all models. The fitted values for β_{sx} are close for the ABMs but different for the PBM since β_{sx} acts on the total egg output in the ABMs but acts on mean worm burden in the PBM.

180

188

Fig 4. Kernel density estimate of EPG in the 2012 data and in the equilibrium state of all models on a regular and on a log scale on the y-axis. The x-axis is plotted on a log scale. The dashed vertical red lines indicate the transition from low to medium and from medium to high EPG burden, respectively. The PBM and the ABM^{Γ} show very strong overlap.

Fig 5 also allows the comparison of the impact prediction of the MDA campaign $_{197}$ with 80% coverage made by the models. There is a remarkable agreement between the 198 predictions of all models with regards to the prevalence and overall mean worm ¹⁹⁹ burden variables (Fig $5a$). The most notable difference is the smaller drop in 200 prevalence predicted by the PBM after the initial distributions of MDA. 201

There is more difference between the predictions of the models in terms of 202 distributional summary statistics (Fig [5b\)](#page-11-0). Most notably, the PBM predicts a sharp $_{203}$ drop in the number of individuals with high worm burden with no more individuals $_{204}$ remaining in this category after 2 years of MDA campaign. While the predictions of ²⁰⁵ the models mostly agree in terms of prevalence of low and medium worm burden, the $_{206}$ mean EPG within these groups shows some disagreement.

Comparing the predictions of the models in Fig 5 with field data measured after $5\ \ 208$ rounds of yearly MDA ("Data 2018"), we see that all models overestimate the 200 remaining prevalence by a factor of almost $2 \times 5a$. All models underestimate worms per human, though the predictions still lie within the confidence interval, which $_{211}$ is large for this variable due to the high degree of aggregation. From Fig $5b$, we see 212 that the overestimation in prevalence is entirely attributable to an overestimation of ²¹³ the prevalence of individuals with a low worm burden, while the prediction of $_{214}$ moderate worm burden prevalence matches the data well and the predicted high worm ²¹⁵ burden prevalence lies below the data though within the confidence interval. ²¹⁶

Fig [6](#page-12-0) depicts the value of the state variables after 5 years of yearly MDA (indicated 217

> by the red dashed vertical lines in Fig [5\)](#page-11-0) for coverages between 0% and 90%. The high $_{218}$ agreement between models for the overall mean and prevalence variables persists over ²¹⁹ the entire range of coverages (Fig $6a$). For the distributional summary statistics, there 220 is more disagreement between the models over the range of coverages, again with the 221 ABM^{Γ} and the PBM being closer together in predictions (Fig [6b\)](#page-12-0). Fig [6](#page-12-0) again includes the 2018 data. We see that no model predicts a reduction prevalence as seen $_{223}$ in the data with any level of coverage between 0% and 90% . On the other hand, all $_{224}$ models predict the reduction in mean worm burden to match the field data at a 225 coverage of 40% , which lies below the estimated coverage 80% under which the 2018 226 data was generated. For the distributional summary statistics, the 2018 data can be 227 reproduced for all variables except for the overall prevalence, the prevalence of low ²²⁸ mean worm burden and the mean EPG in the group of high worm burden. However, ²²⁹ the required coverage for attaining the targets varies over summary statistics.

(a) Time series for overall mean and prevalence summary statistics. All models were calibrated to fit the 2012 data in equilibrium but not the 2018 data.

(b) Time series for distributional summary statistics. Only the ABM^{ε} model was calibrated to fit the 2012 data in equilibrium, none of the models was fit to the 2018 data. Fig 5. Time series showing the mean of the summary statistics from model runs with 10 random seeds for each model variant. The error bands indicate the minimum and maximum values over the random seeds. All runs start at the fitted equilibrium. After 1 year in equilibrium, yearly MDA is conducted at a coverage of 80%.

(a) Mean and prevalence summary statistics after 5 years of MDA campaigns over a range of MDA coverages.

(b) Distributional summary statistics after 5 years of MDA campaigns over a range of MDA coverages.

Fig 6. Summary statistics after 5 years of yearly MDA campaign at the time point indicated by the vertical red dashed line in Fig [5.](#page-11-0) Each model variant is run with 10 random seeds for each MDA coverage and the mean is taken for the respective summary statistic. The error bands show the minimum and maximum values observed over the random seeds. The data from the year 2018 is plotted if available. At an MDA coverage of 80%, the model prediction should ideally match the data, as indicated by the black diamond.

Fig [7](#page-13-0) shows which combinations of education campaign efficacy and variance in the 231 beta distribution of MDA participation ("MDA variance") are required in the model 232 under the assumption of an 80% MDA coverage to achieve the same prevalence and 233 mean worm burden as seen in the 2018 data. Both target prevalence and target mean ²³⁴

> worm burden are achieved at the intersection of the lines which is indicated by the 235 marker labeled "optimum". The ABM^{Γ} requires an MDA variance of 0.24 and an 236 education efficacy of 45% while the ABM^{ε} requires a lower MDA variance of 0.21 as 237 well as a lower education efficacy of 33% . Fig [7](#page-13-0) also indicates which change to the $\frac{238}{248}$ intervention is important for replicating which variable. For both model variants, the ²³⁹ target prevalence can be achieved with a wide range of MDA variance levels while the ²⁴⁰ education efficacy is required to lie in a much narrower band. Therefore, the model $_{241}$ predicts the education campaign to be main driver for the observed reduction in 242 prevalence. Conversely, the heterogeneity in MDA adherence is the main driver of the ²⁴³ observed persistence of substantial mean worm burden across the population. Fig [8](#page-14-0) ²⁴⁴ shows model runs using the optimal values of MDA variance and education campaign $_{245}$ efficacy as indicated in Fig [7.](#page-13-0) The prevalence and mean worm burden now fit the 2018 $_{246}$ data as expected. The distributional summary statistics in Fig [8b](#page-14-0) show that the $_{247}$ reduction in prevalence is mainly achieved by reducing the prevalence of individuals $_{248}$ with low worm burden. In fact, the model prediction of low worm burden prevalence $_{249}$ now fits the 2018 data even though it was not used to fit the adapted intervention 250 characteristics. The increase in mean worm burden by MDA variance is mainly ²⁵¹ achieved through increased prevalence of high mean worm burden. While the models $_{252}$ without MDA variance estimated very little persistence of high worm burden, the 253 models with MDA variance predict high worm burden at the upper end or above the ²⁵⁴ confidence interval of the 2018 data. 255

Fig 7. Required combinations of education campaign efficacy and MDA variance in the agent-based models to attain the same prevalence and intensity of infection as seen in the 2018 data after 5 MDA campaigns with an estimated coverage of 80%. Both target values are met at the intersection of both lines, as indicated by the marker labeled "optimum".

(a) Time series for overall mean and prevalence summary statistics from model runs adapted to match the prevalence and mean worm burden in the 2018 data.

(b) Time series for distributional summary statistics from model runs adapted to match the prevalence and mean worm burden in the 2018 data.

Fig 8. Simulations run with MDA variance and education efficacy such that target reduction in mean worm burden and prevalence can be achieved. The predictions for mean worm burden and prevalence now match the 2018 data. The "baseline" model runs without the adaptations are also plotted for comparison and are the same as in Fig [5.](#page-11-0)

Fig [9](#page-15-0) depicts the evolution of the aggregation parameter k for worms over time under the MDA campaigns with 80% coverage in the PBM as well as the ABMs with $_{257}$ and without fitted education campaigns and heterogeneity in MDA adherence. The 258 field data which is also plotted shows a decrease in the aggregation parameter k when 259 comparing the data from before the MDA campaigns in 2012 to the data collected 260 after MDA campaigns in 2018. Low prevalence after interventions has also been ²⁶¹

> associated with a high degree of aggregation for hookworm infection $[31]$. For the $\frac{262}{262}$ PBM, k is constant by assumption. For the ABMs without education and 263 heterogeneity in MDA adherence, k drops sharply after each round of MDA. This $_{264}$ indicates an increased degree of heterogeneity which occurs because individuals who received MDA are now free of worms and the remaining worm burden is carried only ²⁶⁶ by those 20% of individuals that did not receive MDA. As time passes since the last $_{267}$ round of MDA, individuals that received MDA start acquiring worms again and catch ₂₆₈ up in worm counts compared to those who did not receive MDA which reduces aggregation and therefore increases k . The ABMs with the adapted heterogeneity in $_{270}$ MDA adherence and education campaign exhibit sustained reductions in k . This is $\frac{271}{271}$ because individuals with lowest worm uptake rates are most likely to be reached by 272 the MDA campaign. These individuals are slower to start taking up worms again after $_{273}$ MDA, which would increase prevalence and therefore k. In addition, the education 274 campaigns further reduce the uptake rates of all individuals and therefore slow down ²⁷⁵ the rebound of prevalence after an MDA campaign. The prediction of k perfectly fits 276 the 2018 data for the ABMs with education campaigns and the heterogeneity in MDA $_{277}$ adherence because the MDA variance and education campaign efficacy were chosen to 278 fit the mean worm burden and the prevalence, which are the sole determinants of the $_{279}$ $\arg\!mathrm{regation\ parameter\ }k.$

Fig 9. Time series of aggregation parameter k for worms in indivudals in the model runs depicted in Fig [8.](#page-14-0) For the ABMs, values are calculated by numerically solving Equation (3) for k given the mean worm burden and prevalence at each time step. For the PBM, k is constant over time by assumption.

4 Discussion ²⁸¹

Previous PBMs of *Opisthorchis viverrini* could accurately capture the prevalence of 282 infection in reservoir and intermediate hosts, as well as the prevalence of infection and ₂₈₃ mean worm burden in humans $[15,25]$ $[15,25]$. However, as compartmental models, they could $_{284}$ not capture the distribution of worm burden in humans, nor how the relationship 285 between prevalence of infection and mean worm burden changes due to repeated MDA ²⁸⁶ campaigns. Here, we presented the first AMBs of $O.$ viverrini transmission that allow $_{287}$ us to incorporate heterogeneities among humans in uptake of the parasite and 288 adherence to treatment in order to better reproduce the distribution of worm burden 289 in humans before and after mass-drug administration campaigns.

We conducted a thorough comparison of the ABMs with the PBM to show the 291 utility of both types of models. Both perform similarly well in reproducing the impact ²⁹² of interventions in transmission reduction, again emphasizing the utility of PBMs in ²⁹³ macroparasite modelling. However, the ABMs are better able to capture the distribution changes in response to MDA campaigns when incorporating plausible ²⁹⁵ heterogeneities in MDA adherence combined with education campaigns.

We show that education campaigns, and therefore behavior change, was necessary 297 to explain the reduction in prevalence; and that this could not be explained solely by 298 MDA campaigns. On the other hand, we show that a high degree of heterogeneity in $_{299}$ MDA adherence is a plausible cause for the persistence of high worm burden in some $\frac{300}{200}$ individuals, highlighting the importance of reaching these individuals in future MDA \qquad 301 α campaigns. $\qquad \qquad \text{302}$

The mechanisms of systematic MDA adherence and an education campaign can be $\frac{303}{200}$ easily added to ABMs. For the compartmental model, in contrast, modelling an evolution of the aggregation parameter k would become necessary and it is not clear $\frac{305}{200}$ how heterogeneity in MDA adherence and an education campaign would translate to $\frac{306}{200}$ changes of k (see also Fig [9\)](#page-15-0). In contrast to results from ABMs for hookworm $\frac{307}{200}$ epidemiology and control $[32]$, we find that the aggregation parameter k is not increasingly reduced over multiple yearly MDA campaigns when assuming random $\frac{309}{200}$ adherence due to quick rebounds in infection rates. 310

There are several important factors we have not considered for simplicity or $\frac{311}{211}$ because of data unavailability. MDA campaigns have been conducted in the study ³¹² area prior to 2012, albeit on an irregular basis $[11]$ and we lack data on the timing and $\frac{1}{313}$ the coverage of these campaigns. The assumption of an equilibrium at the start of the $_{314}$ simulation period may therefore be inappropriate and yield parameter fits which $\frac{315}{2}$ underestimate transmission intensities. However, relaxing this assumption would $_{316}$ require additional data on the timing and coverage levels of these interventions. $\frac{317}{200}$

We have also not considered inaccuracies of the EPG measurement technique. $\frac{318}{2}$ Specifically, sensitivity may not be perfect, leading to an underestimation of ³¹⁹ prevalence, and the EPG counts for high worm burden may be subject to large $\frac{320}{200}$ variances. We also assumed MDA to have perfect efficacy, leading to clearance of all $_{321}$ parasites when an individual receives the drug. This assumption is not realistic, $_{322}$ especially in individuals with high worm burden, but there is little data to better $\frac{323}{2}$ estimate the efficacy of the campaigns. Even though we have sample sizes of several $\frac{324}{2}$ hundred individuals, the uncertainty for the proportion of high worm burden ³²⁵ individuals is high as only very few individuals fall into this category. Specifically, for ³²⁶ the year 2012 there were 25 individuals with high worm burden, while in 2018, there $\frac{327}{2}$ were only two individuals. In the absence of data that could provide realistic $\frac{328}{2}$ assumptions of EPG measurement sensitivity or MDA efficacy, we chose the ³²⁹ simplifying but extreme assumption of perfect diagnostic sensitivity and perfect MDA \quad 330 efficacy. \Box

An obvious drawback of the ABM^{ε} is the direct derivation of the transmission 332 parameter distribution from the field data, which means that we are using the data we $\frac{333}{2}$ fit to also to parameterize the model. While this may limit the generalizability of $_{334}$ results, it may be appropriate for studying a specific population. There may also be $\frac{335}{2}$ situations where the field data cannot be captured as well with a gamma distribution, $\frac{336}{2}$ and the results suggest that ABM^{ϵ} may be a valid alternative in such a situation. One $\frac{337}{2}$ could also criticize that ABM^{ϵ} fixes the proportion of people with a worm uptake rate $\frac{338}{2}$ equal to zero and thereby the prevalence at equilibrium. However, the ABM^{Γ} 339 effectively does the same by drawing a low value of $\beta_{h,i}$ for some individuals such $\beta_{h,i}$ that they never have any parasite uptake. While the ABMs allow setting a lot of $_{341}$ parameters at the level of individuals, we often lack information on how to specify $_{342}$

> these variables. For example, the choice of a beta distribution for the MDA adherence ₃₄₃ was chosen for simplicity and may not reflect reality. We also did not include heterogeneity in the efficacy of the education campaign both, for simplicity and due to $\frac{345}{2}$ a lack of data, even though heterogeneity is likely to exist in reality. We expect that ³⁴⁶ including heterogeneity in education campaign efficacy at the individual level will add $_{347}$ a degree of freedom that would allow us to even better model the impact of the $\frac{348}{2}$ interventions on the distribution of worm burden in the population. $\frac{349}{2}$

> A clear next step is to integrate the ABMs with disease models as they better $\frac{350}{350}$ capture individuals with the highest worm burden and therefore the highest risk of $_{351}$ acquiring chronic disease. Furthermore ABMs allow us to track the treatment history ³⁵² and the aggregate worm burden over time of each individual, as well as additional risk $\frac{353}{100}$ factors. Currently ongoing studies associating worm burden and disease will allow the ³⁵⁴ appropriate parameterization of such models that can then be used to predict the ³⁵⁵ impact of interventions on the incidence of cholangiocarcinoma based on the history of ³⁵⁶ infection and treatment at an individual level.

 $\mathbf{References}$ \blacksquare

- 2. Crellen T, Sithithaworn P, Pitaksakulrat O, Khuntikeo N, Medley GF, $_{362}$ Hollingsworth TD. Towards Evidence-based Control of *Opisthorchis viverrini.* 363 Trends in Parasitology. $2021;37(5):370-380$.
- 3. Fürst T, Keiser J, Utzinger J. Global burden of human food-borne ³⁶⁵ trematodiasis: a systematic review and meta-analysis. The Lancet Infectious 366 Diseases. $2012;12(3):210-221$.
- 4. Zhao TT, Feng YJ, Doanh PN, Sayasone S, Khieu V, Nithikathkul C, et al. ³⁶⁸ Model-based spatial-temporal mapping of opisthorchiasis in endemic countries $\frac{369}{200}$ of Southeast Asia. eLife. 2021;10:e59755. ³⁷⁰
- 5. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver 371 fluke induces cholangiocarcinoma. PLOS Medicine. 2007;4(7):e201. 372
- 6. Swangjai P, Riganti M, Bunnag D, Harinasuta T. Clinical features in severe ³⁷³ opisthorchiasis viverrini. Southeast Asian J Trop Med Public Health. ³⁷⁴ $1985;16(3):405-409.$ 375
- 7. Mairiang E, Laha T, Bethony JM, Thinkhamrop B, Kaewkes S, Sithithaworn P, ³⁷⁶ et al. Ultrasonography assessment of hepatobiliary abnormalities in 3359 377 subjects with *Opisthorchis viverrini* infection in endemic areas of Thailand. $\frac{378}{276}$ Parasitology International. 2012;61(1):208–211. 379
- 8. Rim H. Clonorchiasis: an update. Journal of Helminthology. ³⁸⁰ $2005;79(3):269-281.$ 381
- 9. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of ³⁸² liver fluke infection as risk factor for cholangiocarcinoma. Journal of $\frac{383}{383}$ Hepato-Biliary-Pancreatic Sciences. 2014;21(5):301-308.
- 10. Kaewkes S. Taxonomy and biology of liver flukes. Acta Tropica. ³⁸⁵ $2003;88(3):177-186.$ 386

- 12. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. ³⁹¹ Oxford University Press; 1992.
- 13. Woolhouse ME, Dye C, Etard JF, Smith T, Charlwood J, Garnett G, et al. ³⁹³ Heterogeneities in the transmission of infectious agents: implications for the ³⁹⁴ design of control programs. Proceedings of the National Academy of Sciences. 395 $1997;94(1):338-342.$ 396
- 14. Saengsawang P, Promthet S, Bradshaw P. Reinfection by Opisthorchis viverrini ³⁹⁷ after treatment with Praziquantel. Asian Pacific Journal of Cancer Prevention. ³⁹⁸ $2016;17(2):857-862.$ 399
- 15. Bürli C, Harbrecht H, Odermatt P, Sayasone S, Chitnis N. Mathematical $\frac{400}{400}$ analysis of the transmission dynamics of the liver fluke, *Opisthorchis viverrini.* 401 Journal of Theoretical Biology. 2018;439:181–194. ⁴⁰²
- 16. Bürli C. Mathematical modelling of transmission dynamics of *Opisthorchis* 403 viverrini [dissertation on the Internet]. University of Basel, Switzerland; 2019. 404 Available from: <https://edoc.unibas.ch/82003/1/ThesisFinal2021.pdf>. 405
- 17. Echaubard P, León T, Suwanatrai K, Chaiyos J, Kim CS, Mallory FF, et al. $\qquad 406$ Experimental and modelling investigations of *Opisthorchis viverrini* miracidia $\frac{407}{407}$ transmission over time and across temperatures: implications for control. International Journal for Parasitology. $2017;47(5):257-270$.
- 18. Suwannatrai A, Pratumchart K, Suwannatrai K, Thinkhamrop K, Chaiyos J, ⁴¹⁰ Kim C, et al. Modeling impacts of climate change on the potential distribution $\frac{411}{411}$ of the carcinogenic liver fluke, Opisthorchis viverrini, in Thailand. Parasitology ⁴¹² Research. 2017;116(1):243–250. 413
- 19. Dai Y, Gao S, Zhang F, Luo Y. Threshold and stability results for clonorchiasis ⁴¹⁴ epidemic model. Journal of Science, Technology and Environment. ⁴¹⁵ $2013:2(2):1-13.$
- 20. Gao S, Yuan R, Liu Y, Meng X. Modelling the effects of snail control and $\frac{417}{417}$ health education in Clonorchiasis infection in Foshan, China. Complexity. 2019;2019:5878424. 419
- 21. Huang XH, Qian MB, Zhu GH, Fang YY, Hao YT, Lai YS. Assessment of ⁴²⁰ control strategies against *Clonorchis sinensis* infection based on a multi-group dynamic transmission model. PLOS Neglected Tropical Diseases. 422 2020;14(3):e0008152. 423
- 22. Yuan R, Gao S, Huang J, Zhang X. Mathematical modeling the dynamics of ⁴²⁴ clonorchiasis in Guangzhou City of China. Mathematical Biosciences and ⁴²⁵ Engineering. 2019;16(2):881–897.
- 23. Yuan R, Huang J, Zhang X, Ruan S. Modeling the transmission dynamics of $\frac{427}{427}$ clonorchiasis in Foshan, China. Scientific Reports. 2018;8(1):1–9. ⁴²⁸
- 24. Graham M, Ayabina D, Lucas TC, Collyer BS, Medley GF, Hollingsworth TD, ⁴²⁹ et al. SCHISTOX: an individual based model for the epidemiology and control ⁴³⁰ of schistosomiasis. Infectious Disease Modelling. 2021;6:438–447. ⁴³¹

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.09.23289707;](https://doi.org/10.1101/2023.05.09.23289707) this version posted May 11, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted med

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.09.23289707;](https://doi.org/10.1101/2023.05.09.23289707) this version posted May 11, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted med

Supporting information 459

Supplementary information: Detailed model descriptions of ABMs and PBM ⁴⁶⁰